Incidence of Immune Checkpoint Inhibitor-Induced Myocarditis During the COVID-19 Pandemic

J Am Heart Assoc. 2024 Mar 19;13(6):e032667. doi: 10.1161/JAHA.123.032667. Epub 2024 Mar 18.

Affiliations

¹ Department of Internal Medicine, Division of Cardiology University of Michigan Ann Arbor MI USA.
² Department of Biostatistics, School of Public Health University of Michigan Ann Arbor MI USA.
³ Department of Pharmacology Sorbonne Université, INSERM, AP-HP, CIC-1901, Pitié-Salpêtrière Hospital Paris France.

No abstract available

Keywords: COVID‐19; ICI; coronavirus disease; immune checkpoint inhibitor; immunotherapy; myocarditis.

MeSH terms

COVID-19*
Humans
Immune Checkpoint Inhibitors
Incidence
Myocarditis* / chemically induced
Myocarditis* / epidemiology
Pandemics

Substances

Immune Checkpoint Inhibitors

Grants and funding

T32 HL007853/HL/NHLBI NIH HHS/United States